BR112022019114A2 - Dosagem qd de compostos peptídicos agonistas do receptor de gip e usos dos mesmos - Google Patents

Dosagem qd de compostos peptídicos agonistas do receptor de gip e usos dos mesmos

Info

Publication number
BR112022019114A2
BR112022019114A2 BR112022019114A BR112022019114A BR112022019114A2 BR 112022019114 A2 BR112022019114 A2 BR 112022019114A2 BR 112022019114 A BR112022019114 A BR 112022019114A BR 112022019114 A BR112022019114 A BR 112022019114A BR 112022019114 A2 BR112022019114 A2 BR 112022019114A2
Authority
BR
Brazil
Prior art keywords
receptor agonist
agonist peptide
gip receptor
peptide compounds
dosage
Prior art date
Application number
BR112022019114A
Other languages
English (en)
Portuguese (pt)
Inventor
Charles Olivier Henninot Antoine
Cecil Cole Derek
Scorah Nicholas
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of BR112022019114A2 publication Critical patent/BR112022019114A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112022019114A 2020-03-25 2021-03-25 Dosagem qd de compostos peptídicos agonistas do receptor de gip e usos dos mesmos BR112022019114A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062994716P 2020-03-25 2020-03-25
PCT/JP2021/014423 WO2021193984A2 (en) 2020-03-25 2021-03-25 Qd dosing of gip receptor agonist peptide compounds and uses thereof

Publications (1)

Publication Number Publication Date
BR112022019114A2 true BR112022019114A2 (pt) 2023-02-14

Family

ID=76502784

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019114A BR112022019114A2 (pt) 2020-03-25 2021-03-25 Dosagem qd de compostos peptídicos agonistas do receptor de gip e usos dos mesmos

Country Status (18)

Country Link
US (1) US20220227830A1 (enExample)
EP (1) EP4126921A2 (enExample)
JP (1) JP2023519446A (enExample)
KR (1) KR20230005184A (enExample)
CN (1) CN115335395A (enExample)
AR (1) AR121650A1 (enExample)
AU (1) AU2021241257A1 (enExample)
BR (1) BR112022019114A2 (enExample)
CA (1) CA3173129A1 (enExample)
CL (1) CL2022002598A1 (enExample)
CO (1) CO2022014959A2 (enExample)
EC (1) ECSP22074680A (enExample)
IL (1) IL296592A (enExample)
MX (1) MX2022011816A (enExample)
PE (1) PE20230107A1 (enExample)
PH (1) PH12022552562A1 (enExample)
TW (1) TW202202516A (enExample)
WO (1) WO2021193984A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220016215A1 (en) * 2018-09-24 2022-01-20 Takeda Phaarmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
IL296219A (en) * 2020-03-25 2022-11-01 Takeda Pharmaceuticals Co Qw dosing of gip receptor agonist peptide compounds and uses thereof
CN118754965A (zh) 2020-05-29 2024-10-11 北京拓界生物医药科技有限公司 Glp-1和gip受体双重激动剂化合物及其应用
WO2023139106A2 (en) * 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
WO2025154020A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025154021A1 (en) * 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
EP1302462A4 (en) 2000-07-17 2007-07-18 Takeda Pharmaceutical SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF
BR0315815A (pt) 2002-11-01 2005-09-13 Takeda Pharmaceutical Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
CA2597649A1 (en) * 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
JP4094660B1 (ja) 2005-08-10 2008-06-04 武田薬品工業株式会社 糖尿病治療剤
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
AU2007265966B2 (en) 2006-06-27 2012-05-17 Takeda Pharmaceutical Company Limited Fused cyclic compounds
US8497240B2 (en) * 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
CN101573357B (zh) 2006-10-19 2013-01-23 武田药品工业株式会社 吲哚化合物
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
AU2008215490A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of PPAR-gamma
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
CA2872314C (en) * 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
SI2864350T1 (en) * 2012-06-21 2018-08-31 Indiana University Research And Technology Corporation GLUCAGON ANALOGUE ANALOGUE WITH ACTIVITY OF GIP RECEPTOR
DK3004155T3 (da) * 2013-05-28 2022-01-03 Takeda Pharmaceuticals Co Peptidforbindelse
JOP20190211A1 (ar) * 2017-03-31 2019-09-15 Takeda Pharmaceuticals Co ببتيد منشط لمستقبل gip
TWI912614B (zh) * 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
US20220016215A1 (en) * 2018-09-24 2022-01-20 Takeda Phaarmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof

Also Published As

Publication number Publication date
PE20230107A1 (es) 2023-01-25
MX2022011816A (es) 2022-10-10
US20220227830A1 (en) 2022-07-21
CO2022014959A2 (es) 2022-11-08
EP4126921A2 (en) 2023-02-08
WO2021193984A3 (en) 2021-12-16
AU2021241257A1 (en) 2022-10-13
PH12022552562A1 (en) 2022-12-19
AR121650A1 (es) 2022-06-22
KR20230005184A (ko) 2023-01-09
TW202202516A (zh) 2022-01-16
JP2023519446A (ja) 2023-05-10
CN115335395A (zh) 2022-11-11
ECSP22074680A (es) 2022-10-31
WO2021193984A2 (en) 2021-09-30
CA3173129A1 (en) 2021-09-30
CL2022002598A1 (es) 2023-06-02
IL296592A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
BR112023015045A2 (pt) Agonistas de receptores de gpcr, composições farmacêuticas que compreendem os mesmos e métodos para seu uso
BR112022019110A2 (pt) Dosagem qw de compostos peptídicos agonistas do receptor de gip e seus usos
BR112023022836A2 (pt) Agonistas de receptores de glp-1 benzimidazoíla, composições farmacêuticas que compreendem os mesmos e métodos para seu uso
MX2022011816A (es) Dosificacion qd de compuestos peptidicos agonistas del receptor de gip y sus usos.
MX2026002647A (es) Composiciones y metodos de uso que comprenden sustancias con acciones de plasticidad neural administradas a dosificaciones y formulaciones no psicodelicas / psicotomimeticas
CO2021006482A2 (es) Ureas cíclicas
CL2022001743A1 (es) Dosis de gamma-hidroxibutirato (ghb)
BR112016028818A2 (pt) composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo.
BR112022010323A2 (pt) Composto, composto ou sal, medicamento, métodos para ativar um receptor tipo 2 de orexina e para prevenir ou tratar narcolepsia, e, uso do composto ou sal
ECSP18081954A (es) Detección de infección microbiana en heridas
CL2017003436A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
BR112012019101A2 (pt) módulo medicamentoso com botão de uso duplo e sistema de fornecimento de medicamento.
BR112020005841A8 (pt) Peptídeo coagonista do receptor de gcg/glp-1, composição, método para tratar um paciente de uma doença ou distúrbio metabólico, e, uso de um ou mais peptídeos coagonistas.
CL2022001692A1 (es) Compuestos activos frente a receptores nucleares
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
BR112021023110A2 (pt) Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
CR20200061A (es) Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de células b grandes difusas (dlbcl)
BR112021019190A2 (pt) Sistema terapêutico transdérmico
BR112022000155A2 (pt) Composição inibidora da micromolécula pi4kiiia, seu método de preparação, e uso da mesma
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
CO2023011625A2 (es) Uso de luvadaxistat para el tratamiento de deterioro cognitivo
BR112023022445A2 (pt) Composição farmacêutica e uso da combinação farmacêutica
AR045013A1 (es) Metodo para tratar o prevenir trastornos del sistema nervioso central con compuestos que tienen selectividad por la subunidad alfa -3 del receptor de benzodiazepinas
MX2019001696A (es) Combinacion de agonistas inversos de receptor de histamina-3 con inhibidores de acetilcolinesterasa.
CL2016001815A1 (es) Combinación que comprende un ligando de una proteína de la vesícula sináptica 2a y un modulador alostérico positivo o un agonista ortostérico del receptor glutamatérgico metabotrópico de subtipo 2, composición farmacéutica, procedimiento de preparación y uso para el tratamiento o prevención de la epilepsia y trastornos relacionados.